×
0 0 0 -0.0384615384615385 -0.0384615384615385 -0.0673076923076922 -0.076923076923077 -0.0736153846153845
Stockreport

Kedrion Biopharma and Kamada receive FDA approval of KEDRAB for post-exposure prophylaxis against rabies infection; shares ahead 21% premarket [Seeking Alpha]

KAMADA LTD (KMDA)  More Company Research Source: Seeking Alpha
Last kamada ltd earnings: 5/15 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: kamada.com/investors.php
PDF Kedrion Biopharma and Kamada (NASDAQ: KMDA ) announces that KEDRAB [rabies immune globulin (Human)] has received FDA approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. It should be administered concurrently with a full course of rabies vaccine. KEDRAB will launch in the U.S. in early 2018. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two human rabies immune globulin (HRIG) therapy options to prevent the onset of rabies. Under the terms of the agreement, upon receipt of FDA marketing approval, Kamada holds the license for KEDRAB, and Kedrion Biopharma has exclusive rights to commercialize the product in the U.S. With the approval, Kedrion Biopharma expands its portfolio of immune globulin products, which includes RhoGAM and GAMMAKED. KEDRAB is the second product of Kamada approved by the FDA. Shares are up   premarket on light volum [Read more]

IMPACT SNAPSHOT EVENT TIME: KMDA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS